Treating previously untreatable cancers: How CAR‑T cell therapy could be made accessible to more patients
This image was generated by AI and may not depict real events.
Scientists at UCL and Great Ormond Street Hospital have developed a groundbreaking new treatment using genome-edited immune cells to help children and adults fight a rare and aggressive form of blood cancer. The treatment, called BE-CAR7, has shown promising results in clinical trials, with 82% of patients achieving deep remissions and 64% remaining disease-free.
A new treatment for a rare and aggressive form of blood cancer has been developed by scientists at UCL and Great Ormond Street Hospital. The treatment, called BE-CAR7, uses base-edited immune cells to target and destroy cancer cells. In a clinical trial, 10 patients were treated with BE-CAR7, with promising results. The treatment uses a new generation of genome editing called base editing, which avoids cutting DNA and reduces the risk of chromosomal damage. The edited cells are then able to recognize and target specific 'flags' on the surface of cancer cells. The trial results have been published in the New England Journal of Medicine and presented at the American Society of Hematology Annual Meeting.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.